About this trial
Upon successful completion of this study, the investigators expect the study's contribution to be the development of noninvasive imaging biomarkers to predict IEEG functional dynamics and epilepsy surgical outcomes. Findings from the present study may inform current and new therapies to map and alter seizure spread, and pave the way for less invasive, better- targeted, patient-specific interventions with improved surgical outcomes. This research is relevant to public health because over 20 million people worldwide suffer from focal drug-resistant epilepsy and are potential candidates for cure with epilepsy surgical interventions.
Eligibility criteria
Qualifiers
Patients with medication-refractory epilepsy
Planned intracranial EEG (IEEG) placement
Hypothesized to have temporal lobe epilepsy
Disqualifiers
Contraindication to 3T MRI (e.g. metal implants or claustrophobia), clinical features that typically preclude the use of IEEG (e.g. pregnancy), prior intracranial surgery or device, and IEEG findings that are non-diagnostic (e.g. seizure onset zone(s) not identified)
Trial design
Treatments tested in this trial
- 3T Magnetic Resonance Imaging
- Intracranial electroencephalography recordings
- 7T Magnetic Resonance Imaging
Treatment groups
Sponsors and collaborators
University of Pennsylvania
Lead sponsor
Medical University of South Carolina
Collaborator